Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.

Cisplatin: mode of cytotoxic action and molecular basis of resistance

Siddik, Zahid H · 2003 · Oncogene

Abstract

Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1206933

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 154 references

Research works printed but not linked: 5

  1. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH. (1997). Blood, 90, 935–943. · doi:10.1182/blood.v90.3.935.935_935_943 · Paper page
  2. Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R . (1990). Carboplatin: Current Perspectives and Future Directions. Bunn P, Canetta R, Ozols R and Rozencweig M (eds). WB Saunders Company: Philadelphia, PA, pp. 133–140.
  3. He G and Siddik ZH . (2001). Proc. Am. Assoc. Cancer Res., 42, 901.
  4. Holford J, Rogers P and Kelland LR . (1998). Int. J. Cancer, 77, 94–100. · doi:10.1002/(sici)1097-0215(19980703)77:1<94::aid-ijc15>3.0.co;2-9
  5. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF . (2001). Clin. Cancer Res., 7, 2984–2997.

Cited by

See all 3,335

Metadata

Authors
Siddik, Z. H.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Siddik, Zahid H
Venue
Oncogene
Published
2003-10-20
Volume
22
Issue
47
Pages
7265-7279
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2164277862
Cited by
3,335
References
154
Citations by year
2026: 67 · 2025: 94 · 2024: 127 · 2023: 161 · 2022: 195 · 2021: 216 · 2020: 203 · 2019: 181 · 2018: 184 · 2017: 185 · 2016: 215 · 2015: 193 · 2014: 205 · 2013: 175 · 2012: 165
FWCI
7.31
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01ca077332-03)
  • National Cancer Institute (CA-77332, R01CA082361, CA 82361)
Topics
  • Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
cisplatin, cisplatin resistance, DNA adducts, DNA cross-linking, apoptosis, ATR signaling, p53, p73, MAPK signaling, DNA damage response, drug uptake, drug inactivation, DNA repair, HER2/neu, PI3K/Akt signaling, Bcl-2, caspase activation, signal transduction
MeSH terms
Cisplatin, DNA Damage, DNA Repair, Humans, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cisplatin: mode of cytotoxic action and molecular basis of resistance. https://app.cochat.ai/papers/10.1038/sj.onc.1206933
The paper
Siddik, Z. H. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. https://doi.org/10.1038/sj.onc.1206933

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.